Health Care Select Sector SPDR Fund (XLV)
| Assets | $33.25B |
| Expense Ratio | 0.09% |
| PE Ratio | 20.72 |
| Shares Out | 247.02M |
| Dividend (ttm) | $2.39 |
| Dividend Yield | 1.75% |
| Ex-Dividend Date | Jun 23, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | 36.34% |
| Volume | 9,531,563 |
| Open | 136.25 |
| Previous Close | 135.76 |
| Day's Range | 135.74 - 136.70 |
| 52-Week Low | 127.35 |
| 52-Week High | 159.64 |
| Beta | 0.64 |
| Holdings | 62 |
| Inception Date | Dec 16, 1998 |
About XLV
Fund Home PageThe Health Care Select Sector SPDR Fund (XLV) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund tracks health care stocks from within the S&P 500 Index, weighted by market cap. XLV was launched on Dec 16, 1998 and is issued by State Street.
Top 10 Holdings
55.59% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 12.86% |
| Johnson & Johnson | JNJ | 8.28% |
| AbbVie Inc. | ABBV | 6.84% |
| UnitedHealth Group Incorporated | UNH | 5.13% |
| Abbott Laboratories | ABT | 4.44% |
| Merck & Co., Inc. | MRK | 4.29% |
| Thermo Fisher Scientific Inc. | TMO | 3.64% |
| Intuitive Surgical, Inc. | ISRG | 3.56% |
| Amgen Inc. | AMGN | 3.37% |
| Boston Scientific Corporation | BSX | 3.19% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 23, 2025 | $0.63038 | Jun 25, 2025 |
| Mar 24, 2025 | $0.56454 | Mar 26, 2025 |
| Dec 23, 2024 | $0.62166 | Dec 26, 2024 |
| Sep 23, 2024 | $0.57723 | Sep 25, 2024 |
| Jun 24, 2024 | $0.57253 | Jun 26, 2024 |
| Mar 18, 2024 | $0.52294 | Mar 21, 2024 |
Performance
XLV had a total return of -7.39% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.19%.
News
Managed care needs to improve to improve health care sector, says Mizuho's Jared Holz
Jared Holz, Mizuho health care sector strategist, joins 'The Exchange' to discuss the pain in the health care sector and if there are any opportunity plays within.
Trump's deadline looms for Big Pharma companies facing new tariffs
'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.
XLV: Life Expectancy, Patents, And A Positive Outlook Will Pave The Way
The life expectancy has increased in the U.S. and worldwide, contributing to healthcare companies retaining their patients for longer periods. Investors pay low fees to hold XLV, since the expense rat...
Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff
A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.
Measuring Options Activity in MRK & XLV: Healthcare Levels to Watch
Rick Ducat turns to the healthcare sector on today's options analysis. He starts with the SPDR Health Care ETF (XLV), noting the recent breakdown of a head and shoulders pattern and potential for both...
XLV: The S&P 500's Most Discounted Sector? Uncover The Hidden Risk
The healthcare segment, and therefore XLV, is, in terms of relative valuations, the most attractive earning-driven sector. The strong dissonance between earnings expectations and price decline highlig...
2 Healthcare Picks For Distributions And Attractive Valuations
Healthcare CEFs are under pressure from regulatory shifts, but sector defensiveness and discounted valuations can create long-term opportunities. Within the CEF structure, we also have the added benef...
I've never seen a setup this negative for health care job growth, says Bancreek's Pachman
CNBC's “Power Lunch” is joined by Eric Pachman, chief analytics officer at Bancreek Capital Advisors, to discuss the U.S. labor market, whether health care jobs are in jeopardy and more.
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.
Buy America, says John Hancock's Matthew Miskin
Matthew Miskin, John Hancock Investment Management, joins 'The Exchange' to discuss markets, small and mid-caps and the industrial sector.
How pet medicine stocks could cushion your healthcare investments from Trump changes
Moderna shares are seeing a boost on Monday after the US Food and Drug Administration (FDA) gave the pharmaceutical giant limited approval for its lower-dose COVID-19 vaccine. Morgan Stanley Investmen...
The HealthCare Sector: A Look At Sector Earnings Trends
Looking at Q1 '25 earnings trends, the healthcare sector reported a solid quarter, even with UnitedHealth's issues. Q2 and Q3 '25 are showing lower or negative revisions, and lower levels of absolute ...
3 Deep-Value Blue Chips: The Fat Pitch I Couldn't Resist
The worst-case scenario of big global tariffs and a severe recession is now off the table, lowering risk and supporting a new bull market. UnitedHealth offers a Buffett-style deep value opportunity af...
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
Trump is right about drug prices. He's just going about it all wrong.
The stock market doesn't believe the president about prescription drugs.
Final Trade: BABA, JPM, XLV, JBLU
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.
XLV: Trump's Drug Price Talk Revives Old Headlines, Not New Risks
The current market environment is the best I've seen in 30+ years, driven by risk management, blending technical and quantitative analysis, and ignoring most headlines. XLV, the Healthcare Sector SPDR...
StemPoint's Michelle Ross breaks down navigating the pharmaceutical sector volatility
Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss health care's weak week and how to navigate pharma volatility.
Defensive Sectors Continue To Lead U.S. Stock Market This Year
President Trump announced a US-UK trade deal yesterday, which may be an early sign of a thaw in the global trade war. Although the broad US stock market has rebounded sharply in recent weeks, the reco...
Final Trade: SBUX, META, XLV and BABA
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
XLV Vs. VHT: I Prefer XLV For Its Better Downturn Resilience
The Healthcare Sector, represented by XLV and VHT ETFs, offers a defensive investment option amid current market volatility and potential recession risks. Between these two funds, I prefer XLV even be...
Two Stocks To Consider During Market Unrest To Provide Income Stability
Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price st...